Ann: Reminder of Investor Webinar - NanaBis Phase III Trial, page-5

Looks as though the company is overvalued heading into phase 3 and the trials expected to finish next year (2022). From today's close looks as though shares can be bought much cheaper than current MC before phase 3 trial finalises as heavy selling is apparent. With 310 million shares on issues i would expect the share price will be between 10-20c until results start coming in. Nothing special with this company at the moment. Many better cannabis related stocks listed on ASX/US. MXC has a market cap of $140million which entails it is 100% better than MDC's trials and product offering. So today's selloff was no surprise as there seems to be no interest in what the company is doing with it's trials compared to other stocks in the cannabis space around the world. So probably start heading down towards 10-15c very soon.